TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07178951: Safety and Feasibility of the Neurolyser XR Device for the Treatment of Predominantly Medial Chronic Knee Pain Due to Osteoarthritis

Sponsor: FUSMobile Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,278,500

Rescue Site Savings

+$3,484,500

Unlock Full NCT07178951 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07178951 Rescue Dossier →